FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Aligned Medical Solutions Recalls Convenience Kits

Aligned Medical Solutions recalls its custom convenience kits due to the potential for the plunger on the Cardinal Health Monoject Flush Prefilled Syr...

Medical Devices

Meridian Bio EUA for Covid Assay

FDA grants Meridian Bioscience an emergency use authorization for its Revogene SARS-CoV-2 assay, a molecular diagnostic test for the qualitative detec...

Human Drugs

Kalo Paying $12.7 Million to End False Claims Case

The Justice Department says kalo is paying $12.7 million to resolve a whistleblowers allegations that it induced false claims for its Evzio anti-opioi...

Human Drugs

Vektor Medical 510(k) for ECG Mapping Tool

FDA clears a Vektor Medical 510(k) for vMAP, a computational electrocardiogram mapping system for use to improve outcomes in ablation procedures.

Biologics

CHD Wants Probe of FDA Actions on Pfizer Vaccine

Childrens Health Defense calls for a congressional probe of FDAs handling of a whistleblowers complaint about poor research practices at a contractor ...

Medical Devices

Electronic Submission of eSTAR 510(k)s Needed: Consultant

Medical device regulatory consultant Adrienne Lenz says FDA needs to develop a way for medical device manufacturers to transmit electronic 510(k) subm...

Medical Devices

Arthrex Paying $16 Million to Resolve Kickback Case

The Justice Department says Arthrex is paying $16 million to resolve a whistleblowers allegations of kickbacks leading to False Claims Act payments.

Federal Register

Regulatory Review Period Determined for Dojolvi

Federal Register news: FDA determines for patent extension purposes the regulatory review period for Ultragenyxs Dojolvi (triheptanoin).

Federal Register

Info Collection: Antimicrobial Distribution Reporting

Federal Register notice: FDA seeks comments on an information collection extension entitled Antimicrobial Animal Drug Distribution Reports and Recordk...

Human Drugs

Biogen Probes Fatal Case of Aduhelm Patient

Biogen says it is investigating the death of a 75-year-old patient who had taken the companys controversial Alzheimers drug Aduhelm (aducanumab).